Part A - PD-1/PD-L1 blockade in cancer immunotherapy/ Part B - Evaluation of PD-1/PD-L1 immune checkpoint inhibitors in a luciferase-reporter cell-based assay

Part A - PD-1/PD-L1 blockade in cancer immunotherapy/ Part B - Evaluation of PD-1/PD-L1 immune checkpoint inhibitors in a luciferase-reporter cell-based assay

Part A: Molecules that downregulate the immune response are key during cancer treatment because they pose a mechanism to avoid immunotherapy, also called immune checkpoints. In that regard, the PD-1/PD-L1 pathway has been thoroughly studied to deepen our understanding of the function of these immun...

Full description

Bibliographic Details
Main Author: Peredo Aguilar, Maria Azucena
Format: Thesis (University of Nottingham only)
Language:English
Published: 2023
Subjects:
immune checkpoints
cancer cells
immunotherapy
Online Access:https://eprints.nottingham.ac.uk/76035/

Similar Items

Similar Items